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Abstract
Background: In phase I studies, poziotinib has shown meaningful efficacy 
against various types of cancers. This phase 2 study aimed to investigate the ef-
ficacy and safety of poziotinib in recurrent and/or metastatic head and neck squa-
mous cell carcinoma (R/M- HNSCC).
Methods: Overall, 49 patients were enrolled (median age, 62 years; age range, 
21– 78 years). Patients received a median of two prior treatments including chem-
otherapy and others and received 12 mg poziotinib orally once daily as part of a 
28- day cycle. The primary endpoint was objective response rate (ORR), and the 
secondary endpoints were progression- free survival (PFS) and overall survival 
(OS). Targeted capture sequencing was performed using available tissues to iden-
tify translational biomarkers related to clinical response.
Results: ORR was 22.4%, median PFS was 4.0 months (95% confidence interval 
[CI], 1.8– 6.2 months), and median OS was 7.6 months (95% CI, 4.4– 10.8 months). 
The most common treatment- related adverse events were acneiform rash (85%) 
and mucositis (77%). A grade 3 or higher adverse event was acneiform rash (3%). 
Targeted capture sequencing was performed in 30 tissue samples. TP53 and 
PIK3CA were the most frequently mutated genes (43%), followed by CCND1 
(33%) and EGFR (30%). Mutations in ERBB2, ERBB3, and ERBB4, which are HER 
family genes, were observed in 17%, 13%, and 10% samples, respectively. There 
was no difference in the frequency of somatic mutations in the HER family genes 
between the clinically benefitted and non- benefitted groups.
Conclusion: Compared to other pan- HER inhibitors, poziotinib showed clini-
cally meaningful efficacy in heavily treated R/M- HNSCC.
Clinical trial registration number.: NCT02216916.
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1  |  INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is 
the sixth most common cancer worldwide.1,2 Even in ad-
vanced disease, cure is possible through multi- modality 
therapy. However, recurrent and/or metastatic HNSCC 
(R/M- HNSCC) has poor prognosis, with a median sur-
vival of 6– 10 months3,4 and 50– 60% patients develop loco- 
regional or distant recurrence within 2 years.
Epithelial growth factor receptor (EGFR) is frequently 
overexpressed in HNSCC and is associated with poor prog-
nosis.5 The relationship between the EGFR signaling path-
way and tumor survival is well known, as demonstrated 
in several studies. EGFR targeted therapies, especially 
cetuximab, show clinical anticancer effects in HNSCC.3 
In the EXTREME study, when 5FU and cetuximab were 
added to platinum chemotherapy as the primary drug, the 
median OS was 10.1 months compared with 7.4 months 
when only 5FU and platinum chemotherapy were used.6 
However, cetuximab is the only approved targeted agent 
for HNSCC, with a response rate of 10– 15% in patients 
with R/M- HNSCC.7
Anti- programmed cell death 1 (PD- 1) agents, includ-
ing pembrolizumab and nivolumab, were recently ap-
proved for HNSCC that is refractory to platinum- based 
therapy.8- 10 In the Keynote- 048 trial, pembrolizumab 
and pembrolizumab +platinum drug +5- FU were 
used as a new first- line standard of treatment for R/M- 
HNSCC.11 However, the objective response was modest, 
and more effective treatment strategies are needed. In 
addition to immunotherapy, novel targeted therapies, 
such as tyrosine kinase inhibitor (TKI), should be 
developed.
Genomic characterization of HNSCC has recently been 
reported, and amplification of receptor tyrosine kinases, 
including EGFR and ERBB2, was commonly identified in 
HPV- negative HNSCC.12 The amplification of EGFR was 
reported in 15% cases and that of ERBB2 was reported in 
5%, making these the most common gene amplifications. 
Therefore, EGFR and ERBB2  remain viable therapeutic 
targets for patients with HNSCC.12
Poziotinib (HM781- 36B) is an irreversible pan- HER 
TKI that targets EGFR, HER2, and HER4.13 It binds to 
the HER family of tyrosine kinase receptors and blocks 
downstream signaling pathway. Therefore, given the 
public genomic data that EGFR and ERBB2 play an 
important role in the carcinogenesis of HNSCC, we at-
tempted to administer poziotinib to patients to examine 
its efficacy and tolerability. In phase I clinical trials, 
poziotinib showed notable clinical activity against var-
ious types of solid tumors.13,14
In this study, we aimed to demonstrate the efficacy 
and safety of poziotinib in heavily treated R/M- HNSCC 
and identify translational biomarkers related to clinical 
response to poziotinib.
2  |  MATERIALS AND METHODS
2.1 | Study design
This study was a single- center, phase II trial of poziotinib 
monotherapy in R/M- HNSCC patients who exhibited 
disease progression after platinum- based chemotherapy 
or were not eligible for platinum- based chemotherapy 
(ClinicalTrials.gov Identifier: NCT02216916). The ob-
jective response rate (ORR) was the primary endpoint, 
whereas progression- free survival (PFS), OS, and the safety 
profile of poziotinib therapy were the secondary endpoints.
This study was approved by the Institutional Review 
Board of Severance Hospital (4– 2013– 0794). The study 
conforms to the principles for research outlined in the 
Declaration of Helsinki. Written informed consent was 
obtained from all patients before study enrolment.
2.2 | Study population
The subjects were histologically confirmed R/M- HNSCC 
patients in Yonsei Cancer Center. Patients were eligible 
for enrolment if they were aged above 20  years, with an 
Eastern Cooperative Oncology Group performance status 
(ECOG- PS) of 0 to 1, with at least one measurable disease 
based on Response Evaluation Criteria In Solid Tumors 
(RECIST, version 1.1), with documented progression after 
platinum- based systemic chemotherapy, and with a life ex-
pectancy of at least 3 months were included. Chemotherapy- 
naive patients who had inadequate renal function for 
platinum administration could be enrolled in the study.
Patients with more than three lines of previous palliative 
chemotherapy for R/M- HNSCC and previous EGFR tyro-
sine kinase treatments were excluded, except for those who 
had received cetuximab. Patients with nasopharyngeal can-
cer or symptomatic brain metastases were also excluded.
2.3 | Treatment plan
Patients were continuously treated with 12 mg oral pozi-
otinib once daily until disease progression, death, or 
unacceptable adverse events (AEs). The duration of the 
treatment cycle was 28 days. Drug doses were held and/
or reduced for intolerable grade 2 or 3/4 adverse events. 
Up to two dose reductions was allowed (8 mg followed by 
6 mg). If treatment was not resumed within 3 weeks, pa-
tients discontinued the study.
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2.4 | Assessment
Response evaluation was performed every 8 weeks after 
disease progression or when clinically indicated according 
to RECIST 1.1 guidelines.15
Safety assessments included physical examina-
tion, evaluation of AEs, and laboratory tests on day 1 of 
each cycle. All AEs were documented according to the 
Common Terminology Criteria for Adverse Events version 
4.03.16 Patients with clinical benefits were defined as those 
with PFS ≥6 months using poziotinib.
2.5 | Somatic mutation and copy number 
alteration analysis
Formalin- fixed, paraffin- embedded tumor tis-
sues, and blood samples were prepared using the 
Agilent SureSelect Target Enrichment Kit (Agilent 
Technologies, Inc.). Targeted deep sequencing data 
were generated using Illumina NovaSeq 6000 (Illumina) 
with a read length of 101 bp and a mean depth of target 
regions of 1,000X. Read alignment and somatic muta-
tion calling were performed using the DNA Pipeline of 
the Illumina DRAGEN Bio- IT Platform v3.6 (Illumina). 
Tumor somatic mutation annotation was performed 
using Oncotator v1.9.9.0. Somatic copy number altera-
tions (SCNA) were called using CNVkit v0.9.5. A com-
bined somatic mutation and SCNA oncoplot was drawn 
using ComplexHeatmap v2.4.3. Copy number altera-
tions were defined as copy number amplifications (copy 
number >5) and copy number deletions (copy num-
ber = 1 or 0).
2.6 | Statistical rationale for the 
study design
Statistical design was carried out according to Fleming's 
one- stage design. The null hypothesis (P0) with a 5% sig-
nificance level that the ORR is ≤5% versus the alterna-
tive hypothesis (P1) that the ORR is ≥15% was evaluated. 
Forty- four response- evaluable patients were required to 
provide an 80% power to reject P0 when the true ORR was 
15%. With a 10% follow- up loss rate, a total of 49 patients 
were required.
PFS was defined as the time from the start date of pozi-
otinib to progression or death from any cause, and OS was 
defined as the interval from the start date of poziotinib 
therapy to death from any cause. PFS and OS were eval-
uated using the Kaplan– Meier curve and were compared 
using log- rank test. All statistical analyses were performed 
using SPSS version 25.0.17
3  |  RESULTS
3.1 | Patient characteristics
From July 2014 to March 2020, a total of 49 patients were 
enrolled. Patient demographics are listed in Table 1. The 
median age was 62  years (age range, 21– 78  years). The 
number of male patients was 36 (73%). Patients who never 
T A B L E  1  Baseline characteristics (N = 49)





Median(range) 62 (21– 78)
Smoking history









Ethmoid sinus 2 (4.1)












Chemotherapy alone 3 (6.1)
Radiation alone 1 (2.0)
Surgery alone 2 (4.1)
Surgery +RT 0 (0.0)
Surgery +CT 3 (6.1)
Radiation +CT 8 (16.3)
Surgery +RT + CT 32 (65.3)
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smoked accounted for 41% cases, and among smokers, 
those with a smoking history of more than 10  years ac-
counted for 53%.
The most common sites of the primary lesion were the 
oral cavity (28.6%) and oropharynx (28.6%). Furthermore, 
41% of patients had both loco- regional and distant dis-
ease in at least three organs. Three patients (6%) received 
poziotinib as the first- line treatment because of border-
line impairment of renal function. About two- thirds 
(65%) of patients underwent all treatment modalities in-
cluding surgery, chemotherapy, and radiotherapy before 
enrolment.
3.2 | Efficacy and treatment delivery
The response of 49 patients was evaluated (Table  2). 
Five patients were not evaluated because of early with-
drawal. In addition, 22.4% patients (11/49) showed par-
tial response (PR), 53.1% (26/49) showed stable disease 
(SD), and 14.3% (7/49) had progressive disease (PD) as 
the best response (Figure  1). The median duration of 
treatment was 23.1  weeks (95% CI, 13.5– 32.7  weeks). 
The reasons for treatment discontinuation were disease 
progression (n  =  34, 69%), patient withdrawal (n  =  7, 
14%), unacceptable toxicity (n  =  3, 6%), and death 
(n = 5, 10%).
With a median follow- up of 7.6 months (95% CI, 8.1– 
14.3 months), the median PFS was 4.0 months (95% CI, 
1.8– 6.2 months) and the median OS was 7.6 months (95% 
CI, 4.4– 10.8 months) (Figure 2). Median duration of re-
sponse was 8.3 months (95% CI 8.1– 12.2 months). Among 
previous chemotherapy regimens, platinum- based che-
motherapy accounted for 72% cases. Patients had also 
received atezolizumab, durvalumab, M7824, nivolumab, 
and tremelimumab. Two patients had received PI3K in-
hibitors (buparlisib and alpelisib) in other clinical trials. 
Previous chemotherapy regimens administered are de-
scribed in Supplementary Table 1.
3.3 | Safety
As for treatment- related AEs, 48 patients were assessed 
(Table 3). AEs were mainly grade 1– 2 and easily manage-
able. The most common AEs were acneiform rash (85%) 
and mucositis (77%). Grade 3 AEs occurred in five pa-
tients. Grade 3 acneiform rash occurred in two patients, 
grade 3 fatigue in one patient, grade 3  mucositis in one 
patient, and grade 3 lung infection in one patient.
In total, 22 (45.8%) and 16 (33.3%) patients underwent 
dose reduction to 8 and 6  mg due to AEs, respectively. 
Common AEs responsible for dose reduction were acne-
iform rash and mucositis. Four (8.3%) patients discontin-
ued poziotinib therapy due to toxicity, two patients due to 
skin rash, and others due to lung infection.
3.4 | Detection of somatic aberrations
Biomarker analyses were available for 30 patients 
(Figure  3A). Baseline biopsy was not mandatory in this 
trial, and 14 patients had no archival tissues for bio-
marker analysis. Target capture sequencing identified 
a total of 820 point mutations, 6 insertions, and 17 dele-
tions, but in this report, we presented the alterations of 
the 18 genes previously implicated in the TCGA HNSCC 
database.12  The median sequencing depth in the target 
regions was greater than 1,000X. The frequency of so-
matic mutations is illustrated in Figure 3. TP53 (R282W, 
R273C, R248G, G245V, Y205C, H193R, R175H, E11Q) and 
PIK3CA (N345I, R832L) were the most frequently altered 
genes (43%) followed by CCND1 (E70*) (33%) and EGFR 
(P518L, R574L, P753Q, R836S, P848Q, G901W) (30%). 
Alterations in ERBB2 (R978S), ERBB3 (G623E, R1173W), 
and ERBB4 (L713W, R393L, W10L), which are HER fam-
ily genes, were observed in 17%, 13%, and 10% patients, 
respectively (Figure  3B). Detailed mutation profiles are 
summarized in Table S3.
Most DNA copy number amplifications and dele-
tions were also observed in genes involved in cell cycle 
(CDKN2A and CCND1), receptor tyrosine kinase (FGFR1, 
EGFR, and ERBB2), and genes related to proliferation 
(PIK3CA). Copy number amplifications were observed 
in PIK3CA, EGFR, ERBB2, MYC, DDR2, and FGFR1, 
whereas copy number deletions were observed in TP53, 
FGFR3, CDKN2A, HRAS, FGFR2, PTEN, and PIK3R1 
(Figure 3A,B).
Additional clinical information on tissues used for tar-
get capture sequencing is provided in Table S2.
T A B L E  2  Best response by treatment (N = 49)
Characteristic Patients, n (%)
Best response
Complete response 0 (0.0)
Partial response 11 (22.4)
Stable disease 26 (53.1)
Progressive disease 7 (14.3)
Not evaluateda 5 (10.2)
Best overall response rate
95% CI 22.4% (13.0– 35.9)
Abbreviation: CI, confidence interval.
aResponse was not evaluable in five patients because of withdrawal from the 
study.
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3.5 | Association of somatic alterations 
with clinical outcomes
Kaplan– Meier curves of median PFS (4.0  months) and 
OS (7.6 months) are shown in Figure 1. There was no dif-
ference in the frequency of somatic mutations in EGFR, 
ERBB2, ERBB3, and ERBB4 between the clinically ben-
efitted and non- benefitted groups. The median PFS (5.8 
vs. 2.8 months; log- rank test, p = 0.180; Figure 4A) and 
median OS (12.0 vs. 5.9 months; log- rank test, p = 0.093; 
Figure 4B) were not different according to the presence of 
HER family gene mutations. Regarding other genetic al-
terations in the PIK3CA/Akt pathway, cell cycle machin-
ery, and FGFR pathway, there was no statistical difference 
in survival according to the presence of alterations.
4  |  DISCUSSION
We investigated the efficacy and safety of poziotinib in 
heavily treated R/M- HNSCC and identified translational 
biomarkers related to clinical response to poziotinib. 
Characterization of somatic mutation, DNA copy num-
ber, and gene expression was performed.
Patients with HNSCC exhibiting disease progression 
after platinum- based chemotherapy have poor prognosis 
and limited treatment options.8 Based on the results of 
the EXTREME study that showed overall survival benefits 
with no decrease in the quality of life, the research interest 
on EGFR inhibitors has increased.7
However, despite numerous research efforts targeting 
EGFR, drugs developed to date have shown limited activ-
ity in patients with HNSCC. Suppression of EGFR with 
tyrosine kinase inhibitors including gefitinib, erlotinib, 
and lapatinib showed a limited response.18- 21 As a single 
agent, cetuximab in R/M- HNSCC showed limited activ-
ity (ORR13%, time to progression of 70 days; ref.12).7 The 
drug with higher ORR was followed by cetuximab and 
500 mg of gefitinib. However, 500mg of gefitinib in R/M- 
HNSCC also reached only 10.6% ORR, 3.4  months PFS, 
and 8.1 months OS.22 In Phase 2 study with lapatinib, a 
competitive reversible inhibitor of EGFR and ERBB2, no 
F I G U R E  1  Best response for target lesions by patient, based on maximal percentage changes from the baseline (N = 44). Of 49 patients, 



























F I G U R E  2  Kaplan– Meier curves 
of PFS (A) and OS (B) (N = 48). PFS, 
progression- free survival; OS, overall 
survival
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complete or partial responses were observed, and stable 
disease was the best response.23
Poziotinib is considered a new treatment option as a 
promising TKI in carcinomas with EGFR mutations.24 
Compared with previous studies on EGFR TKIs, our study 
showed comparable data with the ORR of 22.4%, median 
PFS of 4.0 months, and OS of 7.6 months. Among patients 
with R/M- HNSCC who exhibited disease progression after 
platinum- based chemotherapy or who were not eligible for 
platinum- based chemotherapy, treatment with poziotinib 
showed longer survival than that with the standard therapy.
Poziotinib showed similar toxicity to other pan- HER 
inhibitors, but it might be related to early dose reduction 
due to AEs. The most common AEs were acneiform rash 
and mucositis, and most patients showed manageable tox-
icity of grades 1– 2. These AEs could be managed through 
supportive care and oral medications.
Our study did not show an association between any 
EGFR mutation and the response to poziotinib. This may 
be because of the small sample size of our study. Although 
there was no statistical difference between patients with 
or without EGFR mutation, median OS increased in pa-
tients with EGFR mutation.
Recently, numerous studies on immunotherapy in patients 
with R/M- HNSCC showed noticeable responses.8,25  The 
recurrence and metastasis of HNSCC are facilitated by im-
mune evasion,26 which is mediated in part by the expression 
of programmed death- ligand (PD- L1 and PD- L2), which 
binds to the T- cell suppressive immune checkpoint receptor 
PD- 1.22,27
In a preclinical study, activation of the EGFR pathway 
induced PD- L1 expression and enhanced susceptibility of 
the lung tumors to PD- 1 blocker, suggesting that a combi-
nation of PD- 1 blocker with EGFR TKIs may be a promis-
ing treatment to extend the duration of response and delay 
resistance.28,29  Thus, the combination of EGFR TKI with 
immunotherapy may show better responses in HNSCC. In 
addition, in case of elderly patients or patients who are ineli-
gible for cytotoxic chemotherapy, the combination of immu-
notherapy and poziotinib is expected to be effective without 
severe toxicity. However, these attempts (NCT03695510) 
should be further validated in prospective trials.
The limitation of this study is that it is a single- center, 
single- arm study with a relatively small number of pa-
tients available for response assessment. The response 
was not evaluated in five patients because of early with-
drawal. One patient withdrew consent without taking 
poziotinib. Two patients withdrew consents before the 
first response evaluation due to decreased general con-








Rash acneiform 41 (85%) 39 (82%) 2 (3%)
Paronychia 14 (29%) 14 (29%) 0
Pruritus 12 (25%) 12 (25%) 0
Palmar- plantar 
Erythrodysesthesia
4 (8%) 4 (8%) 0
Fatigue 12 (25%) 11 (23%) 1 (2%)
General weakness 2 (3%) 2 (3%) 0
Dry skin 3 (6%) 3 (6%) 0
Conjunctivitis 2 (3%) 2 (3%) 0
Fever 1 (2%) 1 (2%) 0
Lung infection 1 (2%) 0 1 (2%)
Nausea 4 (8%) 4 (8%) 0
Vomiting 1 (2%) 1 (2%) 0
Weight loss 3 (6%) 3 (6%) 0
Paresthesia 1 (2%) 1 (2%) 0
Insomnia 1 (2%) 1 (2%) 0
Mucositis 37 (77%) 36 (75%) 1 (2%)
Diarrhea 27 (56%) 27 (56%) 0
Gastrointestinal pain 1 (2%) 1 (2%) 0
Creatinine increased 2 (3%) 2 (3%) 0
Hyperkalemia 1 (2%) 1 (2%) 0
aOne patient was not evaluable because of early withdrawal from the study.
T A B L E  3  Treatment- related AEs 
(N = 48)
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the investigator due to lung infection of grade 3 or higher 
and general weakness. The last patient died of sudden car-
diac death, which was not considered to be related to the 
drug. Additionally, frequent low- grade and serious grade 3 
or greater skin rash and mucositis need careful monitor-
ing and frequent intervention. However, we believe that 
pre- emptive dose reduction and active prevention and 
education of adverse events could raise the adherence and 
efficacy of this drug.
In conclusion, compared with other previous EGFR 
TKIs, poziotinib showed clinically meaningful efficacy 
with manageable toxicity in patients with platinum- 
refractory R/M- HNSCC. Owing to the small number of 
tissues available for targeted capture sequencing, we could 
F I G U R E  3  (A) Somatic mutation, gene copy number, and gene expression profiles between the non- clinically benefitted (PFS 
<6 months) and clinically benefitted (PFS ≥6 months) (N = 30) groups. (B) Somatic mutations and copy number for EGFR, ERBB2, ERBB3, 
and ERBB4 (N = 30)
Clinical benefit         No clinical benefit
Clinical benefit         No clinical benefit
(A)
(B)
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not identify useful biomarkers involved in the response to 
poziotinib. The identification of molecular markers that 
could predict clinical response to targeted therapy will aid 
in the development of personalized targeted treatment, 
which should be the focus of future studies.
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